Optimal Strategies to Reduce Cardioembolic Risk in the Patient with Nonvalvular Atrial Fibrillation: A Patient Centered Approach- Identify the factor(s) in the coagulation cascade on which warfarin, dabigatran, rivaroxaban and apixaban exert their respective anticoagulant effects.
Identify sources for evidence-based guidelines for antithrombotic therapy in the reduction of cardioembolic risk in the patient with non-valvular atrial fibrillation.
Define the impact of renal function, clinical history, and patient age on the choice of anticoagulant agent.
Describe the role of effective clinician/patient communication in the safe management of oral anticoagulation.
Outline an efficient method of incorporating shared decision making when developing a treatment plan for the patient with NVAF.
2.25 Free CEUs for Nurse Practitioners which includes 1.0 Free Pharmacology Hours